Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Pulmonary Tuberculosis Clinical Trial

Official title:
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Status Completed

Clinical Trial Summary

This trial aims to determine whether the early bactericidal activity of rifampicin given with faropenem or cefadroxil (each given with amoxicillin/clavulanic acid) is greater than the activity of rifampicin alone in patients with pulmonary TB. The trial will also investigate potential new biomarkers of sterilising activity.

Clinical Trial Description

Tuberculosis (TB) remains one of the leading causes of mortality from an infectious disease worldwide with approximately 2 million deaths annually. There is an urgent need to identify new drugs, especially drugs with activity against persistent organisms that may enable shorter treatment regimens. Beta-lactam antibiotics have activity against TB in vitro and in animal models and there is evidence of synergy with rifampicin, one of the standard TB drugs. Amongst oral beta-lactam antibiotics, two appear to have optimal properties and optimal synergy with rifampicin and may be candidates for adjunctive treatment of drug-sensitive TB: faropenem (an oral penem, closely related to the carbapenem class) and cefadroxil (a first generation cephalosporin). Both drugs are used widely for the treatment of bacterial infections. They have in vitro activity against Mycobacterium tuberculosis, which is augmented when administered with rifampicin.

This is a Phase II randomised, controlled, open-label, early bactericidal activity trial. We will recruit patients between the ages of 18 and 70 with newly-diagnosed smear positive pulmonary TB, who have not yet started TB therapy.

Patients will be randomised into one of 3 arms to take faropenem (with amoxicillin/clavulanic acid) plus rifampicin, or cefadroxil (with amoxicillin/ clavulanic acid) plus rifampicin, or rifampicin alone for the first two days of the study. Patients will start standard TB therapy on the third day of the study and continue with the beta lactam antibiotics for the remaining 5 days of the study. Following the completion of the 7 days of study medication, the study will end and patients will continue standard combination TB therapy under normal clinical follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02381470
Study type	Interventional
Source	National University Hospital, Singapore
Contact
Status	Completed
Phase	Phase 2
Start date	February 11, 2019
Completion date	October 2, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736864` - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae	N/A
Not yet recruiting	`NCT04055441` - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed	`NCT02349841` - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis	Phase 2
Completed	`NCT01927159` - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers	Phase 1
Active, not recruiting	`NCT01691534` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)	Phase 2
Completed	`NCT00803322` - Improving Community Based Tuberculosis Care in Ethiopia	Phase 4
Completed	`NCT00834353` - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis	N/A
Withdrawn	`NCT03277742` - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz	N/A
Completed	`NCT00057434` - Vitamin A Therapy for Tuberculosis	Phase 3
Not yet recruiting	`NCT06192160` - Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis	Phase 2
Recruiting	`NCT06127641` - Rehabilitation of People With Post-tuberculosis Lung Disease	N/A
Recruiting	`NCT06058299` - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis	Phase 2
Completed	`NCT04550832` - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)	Phase 2
Completed	`NCT02912832` - Prospective Assessment of TBDx Feasibility	N/A
Completed	`NCT01215851` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)	Phase 2
Recruiting	`NCT01503099` - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease	N/A
Completed	`NCT04608955` - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081	Phase 2
Recruiting	`NCT05046366` - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed	`NCT05896930` - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis	Phase 2
Completed	`NCT02279875` - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)	Phase 2